信号通路介导乳腺癌内分泌治疗耐药的研究进展(3)
參考文献
[1]中国乳腺癌内分泌治疗专家共识专家组.中国乳腺癌内分泌治疗专家共识(2015版)[J].中国癌症杂志，2015，25(9)：755-760
[2] Cancer Genome Atlas Network.Comprehensive molecular portraits of human breast tumours[J].Nature，2012，490(7418)：61-70.
[3] Coates A S，Winer E P，Goldhirsch A，et al.Tailoring therapies-improving the management of early breast cancer： St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015[J].Ann Oncol，2015，26(8)：1533-1546.
, 百拇医药
[4] Ziauddin M F，Hua D，Tang S C.Emerging strategies to overcome resistance to endocrine therapy for breast cancer[J].Cancer Metastasis Rev，2014，33(2-3)：791-807.
[5] Fan W，Chang J，Fu P.Endocrine therapy resistance in breast cancer：current status，possible mechanisms and overcoming strategies[J].Future Med Chem，2015，7(12)：1511-1519.
[6] Chia S，Gandhi S，Joy A A，et al.Novel agents and associated toxicities of inhibition of the pi3k/Akt/mtor pathway for the treatment of breat cancer[J].Curr Oncol，2015，22(1)：33-48.
, 百拇医药
[7] Provenzano A，Kurian S，Abraham J.Overcoming endocrine resistance in breast cancer：role of the PI3K and the mTOR pathways[J].Expert Rev Anticancer Ther，2013，13(2)：143-147.
[8] Ciruelos Gil E M.Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positivebreast cancer[J].Cancer Treat Rev，2014，40(7)：862-871.
[9] Hurtado A，Holmes K A，Geistlinger T R，et al.Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen[J].Nature，2008，456(7222)：663-666.
, http://www.100md.com
[10] Knowlden J M，Hutcheson I R，Jones H E，et al.Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells[J].Endocrinology，2003，144(3)：1032-1044.
[11] Osborne C K，Schiff R.Growth factor receptor Cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer[J].Breast，2003，12(6)：362-367.
[12] Holohan C，Van Schaeybroeck S，Longley D B，et al.Cancer drug resistance：an evolving paradigm[J].Nat Rev Cancer，2013，13：714-726.
, 百拇医药
[13] Brodie A，Jelovac D，Sabnis G，et al.Model systems： mechanisms involved in the loss of sensitivity to letrozole[J].
J Steroid Biochem Mol Biol，2005，95(5)：41-48.
[14] Lui A， New J， Ogony J， et al. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells[J].Bmc Cancer，2016，16：487.
[15] Bachelot T，Bourgier C，Cropet C，et al.Randomized phase Ⅱ trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive， human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors：a GINECO study[J].J Clin Oncol，2012，30(22)：2718-2724., 百拇医药(范凤凤 郭宇)
[1]中国乳腺癌内分泌治疗专家共识专家组.中国乳腺癌内分泌治疗专家共识(2015版)[J].中国癌症杂志，2015，25(9)：755-760
[2] Cancer Genome Atlas Network.Comprehensive molecular portraits of human breast tumours[J].Nature，2012，490(7418)：61-70.
[3] Coates A S，Winer E P，Goldhirsch A，et al.Tailoring therapies-improving the management of early breast cancer： St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015[J].Ann Oncol，2015，26(8)：1533-1546.
, 百拇医药
[4] Ziauddin M F，Hua D，Tang S C.Emerging strategies to overcome resistance to endocrine therapy for breast cancer[J].Cancer Metastasis Rev，2014，33(2-3)：791-807.
[5] Fan W，Chang J，Fu P.Endocrine therapy resistance in breast cancer：current status，possible mechanisms and overcoming strategies[J].Future Med Chem，2015，7(12)：1511-1519.
[6] Chia S，Gandhi S，Joy A A，et al.Novel agents and associated toxicities of inhibition of the pi3k/Akt/mtor pathway for the treatment of breat cancer[J].Curr Oncol，2015，22(1)：33-48.
, 百拇医药
[7] Provenzano A，Kurian S，Abraham J.Overcoming endocrine resistance in breast cancer：role of the PI3K and the mTOR pathways[J].Expert Rev Anticancer Ther，2013，13(2)：143-147.
[8] Ciruelos Gil E M.Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positivebreast cancer[J].Cancer Treat Rev，2014，40(7)：862-871.
[9] Hurtado A，Holmes K A，Geistlinger T R，et al.Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen[J].Nature，2008，456(7222)：663-666.
, http://www.100md.com
[10] Knowlden J M，Hutcheson I R，Jones H E，et al.Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells[J].Endocrinology，2003，144(3)：1032-1044.
[11] Osborne C K，Schiff R.Growth factor receptor Cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer[J].Breast，2003，12(6)：362-367.
[12] Holohan C，Van Schaeybroeck S，Longley D B，et al.Cancer drug resistance：an evolving paradigm[J].Nat Rev Cancer，2013，13：714-726.
, 百拇医药
[13] Brodie A，Jelovac D，Sabnis G，et al.Model systems： mechanisms involved in the loss of sensitivity to letrozole[J].
J Steroid Biochem Mol Biol，2005，95(5)：41-48.
[14] Lui A， New J， Ogony J， et al. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells[J].Bmc Cancer，2016，16：487.
[15] Bachelot T，Bourgier C，Cropet C，et al.Randomized phase Ⅱ trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive， human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors：a GINECO study[J].J Clin Oncol，2012，30(22)：2718-2724., 百拇医药(范凤凤 郭宇)
参见：首页 > 医疗版 > 疾病专题 > 普通外科 > 乳腺癌